4-amino-butyric acid 2-{4-[3-(2-chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethyl ester | 751477-01-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 4-amino-butyric acid 2-{4-[3-(2-chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethyl ester
• 英文别名: Perphenazine 4-aminobutyrate；2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethyl 4-aminobutanoate
• CAS: 751477-01-7
• 化学式: C₂₅H₃₃ClN₄O₂S
• 分子量: 489.082
• InChiKey: BABFYCSPNDKXRI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  7

ADMET

代谢

BL-1020，口服给药后，完整地穿过血脑屏障，并被代谢为GABA和氯丙嗪。

BL-1020, after oral administration, crosses the blood brain barrier intact and is metabolized to GABA and perphenazine.

来源:DrugBank

吸收、分配和排泄

• 吸收

口服可用。

Orally available.

来源:DrugBank

反应信息

• 作为反应物：
  描述：

  4-amino-butyric acid 2-{4-[3-(2-chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethyl ester 、 草酸 生成
  参考文献：
  名称：

  WO2006/131923

  摘要：

  公开号：
• 作为产物：
  描述：

  奋乃静 在 4-二甲氨基吡啶 、 甲烷磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 4-amino-butyric acid 2-{4-[3-(2-chloro-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethyl ester
  参考文献：
  名称：

  WO2006/131923

  摘要：

  公开号：

文献信息

• CONJUGATED PSYCHOTROPIC DRUGS AND USES THEREOF
  申请人：Nudelman Abraham

  公开号：US20120309748A1

  公开（公告）日：2012-12-06

  Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.

  本发明揭示了精神药物和有机酸的新型化学结合物，其用途包括治疗精神病和/或增生性疾病，作为化疗增敏剂，并且还揭示了它们的合成方法。所选有机酸被选择为减少精神药物引起的副作用和/或发挥抗增殖活性。
• Salts of conjugated psychotropic drugs and processes of preparing same
  申请人：Ramot at Tel-Aviv University Ltd.

  公开号：EP2272537A2

  公开（公告）日：2011-01-12

  Novel chemical conjugates of a psychotropic drug residue and an amino-containing organic acid residue selected to reduce side effects induced by the psychotropic drug when administered per se, to enhance the therapeutic activity of the psychotropic drug and/or to exert anti-proliferative activity, in which the amino group is in the form of an acid addition salt thereof and which are characterized by high stability are disclosed. Further disclosed are processes for preparing the chemical conjugates and addition salts thereof, pharmaceutical compositions containing the chemical conjugates and methods utilizing the chemical conjugates for treating various medical conditions.

  本发明公开了由一种精神药物残基和一种含氨基有机酸残基组成的新型化学共轭物，这些化学共轭物被选择用于减少精神药物本身给药时引起的副作用、增强精神药物的治疗活性和/或发挥抗增殖活性，其中氨基以其酸加成盐的形式存在，其特点是稳定性高。还公开了制备化学共轭物及其加成盐的工艺、含有化学共轭物的药物组合物以及利用化学共轭物治疗各种病症的方法。
• NOVEL SALTS OF CONJUGATED PSYCHOTROPIC DRUGS AND PROCESSES OF PREPARING SAME
  申请人：Ramot at Tel Aviv University Ltd.

  公开号：EP1888120B1

  公开（公告）日：2012-12-05
• METHODS OF IMPROVING COGNITIVE FUNCTIONS
  申请人：BIOLINERX LTD.

  公开号：EP2509603A1

  公开（公告）日：2012-10-17
• Conjugated psychotropic drugs and uses thereof
  申请人：Nudelman Abraham

  公开号：US20070099977A1

  公开（公告）日：2007-05-03

  Novel chemical conjugates of psychotropic drugs and organic acids, uses thereof in the treatment of psychotic and/or proliferative disorders and diseases and as chemosensitizing agents, and their syntheses are disclosed. The organic acids are selected to reduce side effects induced by the psychotropic drugs and/or to exert an anti-proliferative activity.